Description
Inherited retinal dystrophy can be caused by recessive variants in the RPE65 gene. Patients with biallelic variants have difficulty seeing in dim light and progressive loss of vision. These disorders are rare and have traditionally been considered untreatable. Gene therapy with an adeno-associated virus vector expressing RPE65 has been proposed as a treatment to improve visual function.

For individuals who have vision loss due to biallelic RPE65 variant-associated retinal dystrophy who receive gene therapy, the evidence includes randomized controlled trials and uncontrolled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Biallelic RPE65 variant-associated retinal dystrophy is a rare condition and, as such, it is recognized that there will be particular challenges in generating evidence, including recruitment for adequately powered randomized controlled trials, validation of novel outcome measures, and obtaining long‐term data on safety and durability. There are no other U.S. Food and Drug Administration-approved pharmacologic treatments for this condition. One randomized controlled trial (N = 31) comparing voretigeneneparvovec with a control demonstrated greater improvements on the Multi-Luminance Mobility Test, which measures the ability to navigate in dim lighting conditions. Most other measures of visual function were also significantly improved in the voretigeneneparvovec group compared with the control group. Adverse events were mostly mild to moderate. However, there is limited follow-up available. Therefore, the long-term efficacy and safety are unknown. Based on a small number of patients from early phase studies, voretigeneneparvovec appears to have durable effects to at least 3 years. Other gene therapies tested in early phase trials have shown improvements in retinal function but variable durability of effect; some patients from 2 cohorts who initially experienced improvements have subsequently experienced declines after 1 to 3 years. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Objective
The objective of this evidence review is to determine whether gene augmentation therapy improves the net health outcome for patients with vision loss due to biallelic RPE65 variant-associated retinal dystrophy.

Background
Inherited Retinal Dystrophies
Inherited retinal dystrophies are a diverse group of disorders with overlapping phenotypes characterized by progressive degeneration and dysfunction of the retina.¹ The most common subgroup is retinitis pigmentosa, which is characterized by a loss of retinal photoreceptors, both cones and rods. The hallmark of the condition is night blindness (nyctalopia) and loss of peripheral vision. These losses lead to difficulties in performing visually dependent activities of daily living such as orientation and navigation in dimly lit areas. Visual acuity may be maintained longer than peripheral vision, though eventually, most individuals progress to vision loss.

RPE65 Gene
Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) both have subtypes related to pathogenic variants in RPE65. RPE65 (retinal pigment epithelium-specific protein 65-kD) gene encodes the RPE54 protein is an all-trans-retinal isomerase, a key enzyme expressed in the retinal pigment epithelium (RPE) that is responsible for regeneration of 11-cis-retinol in the visual cycle.² The RPE65 gene is located on the short (p) arm of chromosome 1 at position 31.3 (1p31.3). Individuals with biallelic variations in RPE65 lack the RPE65 enzyme; this lack leads to build-up of toxic precursors and damage to RPE cells, loss of photoreceptors, and eventually complete blindness.³

Epidemiology
RPE65-associated inherited retinal dystrophy is rare. The prevalence of LCA has been estimated to be between 1 in 33,000 and 1 in 81,000 individuals in the United States.^4,5 LCA subtype 2 (RPE65-associated LCA) accounts for between 5% and 16% of cases of LCA.^4,6,7,8 The prevalence of RP in the United States is approximately 1 in 3,500 to 1 in 4,000⁹ with approximately 1% of patients with RP having RPE65 variants.¹⁰ Assuming a United States population of approximately 330.6 million at the end of 2020,¹¹ the prevalence of RPE65-associated retinal dystrophies in the United States would, therefore, be roughly 1,000 to 2,500 individuals. Table 1 summarizes the estimated pooled prevalence of RPE-associated inherited retinal dystrophy and the range of estimated cases based on the estimated 2017 United States population.

Table 1. Estimated Pooled Prevalence of RPE65-Associated Inherited Retinal Dystrophy and Estimated Number of Patients

LCA type 2: Leber congenital amaurosis type 2; RP: retinitis pigmentosa.

Gene Therapy
Gene therapies are treatments that change the expression of genes to treat disease, e.g., by replacing or inactivating a gene that is not functioning properly or by introducing a new gene. Genes may be introduced into human cells through a vector, usually a virus.¹² Adeno-associated viruses (AAV) are frequently used due to their unique biology and simple structure. These viruses are in the parvovirus family and are dependent on coinfection with other viruses, usually adenoviruses, to replicate. AAVs are poorly immunogenic compared with other viruses but can still trigger immune response making it a challenge to deliver an effective dose without triggering an immune response that might render the gene therapy ineffective or harm the patient.³ There are over 100 different AAVs, and 12 serotypes have been identified so far, labeled AAV1 to AAV12; in particular, AAV2, AAV4, and AAV5 are specific for retinal tissues. The recombinant AAV2 is the most commonly used AAV serotype in gene therapy.¹³

The eye is a particularly appropriate target for gene therapy due to the immune privilege provided by the blood-ocular barrier and the minimal amount of vector needed, given the size of the organ. Gene therapy for RPE65 variant-associated retinal dystrophy using various AAV vectors to transfect cells with a functioning copy of RPE65 in the RPE cells has been investigated.

Regulatory Status
On December 19, 2017, the AAV2 gene therapy vector voretigeneneparvovec-rzyl (Luxturna™; Spark Therapeutics) was approved by the U.S. Food and Drug Administration for use in patients with vision loss due to confirmed biallelic RPE65 variant-associated retinal dystrophy. Spark Therapeutics received breakthrough therapy designation, rare pediatric disease designation, and orphan drug designation.

Policy 
Adeno-associated virus vector-based gene therapy via subretinal injection with voretigene neparvovec is considered MEDICALLY NECESSARY for patients with vision loss due to biallelic RPE65 variant-associated retinal dystrophy if they meet all of the following criteria:

• Patient is 12 months of age or older
• Documentation of the following:
  • Genetic testing confirming presence of biallelic RPE65 pathogenic variant(s) or likely pathogenic variants (see Policy Guidelines for additional details)
    • Single RPE65 pathogenic variant or likely pathogenic variant found in the homozygous state
    • Two RPE65 pathogenic variants or likely pathogenic variants found in the trans configuration (compound heterozygous state) by segregation analysis
• Presence of viable retinal cells as determined by treating physicians as assessed by optical coherence tomography imaging and/or ophthalmoscopy:
  • An area of retina within the posterior pole of > 100 μm thickness shown on optical coherence tomography
• Used for the treatment of vision loss defined by one of the following:
  • Visual acuity worse than 20/60 in both eyes
  • Visual field less than 20 degrees in any meridian as measured by III4e isopter or equivalent in both eyes
• Prescribed by or in consultation with one of the following physicians associated with an ocular gene therapy treatment Center of Excellence:
  • Ophthalmologist
  • Retinal specialist/surgeon
• Administered by a retinal specialist/surgeon experienced in performing intraocular surgery
• Patient has not previously received RPE65 gene therapy in the intended eye
• Do not have any of the following:
  • Pregnancy in females or Breastfeeding
  • Use of retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme; individuals who discontinue use of these compounds for 18 months may become eligible
  • Prior intraocular surgery within 6 months
  • Preexisting eye conditions or complicating systemic diseases that would preclude the planned surgery or interfere with the interpretation of study. Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (e.g., radiotherapy of the orbit; leukemia with central nervous system/optic nerve involvement). Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g., macular edema, proliferative changes). Also excluded would be subjects with immunodeficiency (acquired or congenital) because they could be susceptible to opportunistic infection (e.g., cytomegalovirus retinitis).

Other applications of voretigene neparvovec are investigational/unproven and therefore is considered NOT MEDICALLY NECESSARY. 

Policy Guidelines
The recommended dose of voretigene neparvovec-rzyl for each eye is 1.5 × 10¹¹ vector genomes (vg), administered by subretinal injection in a total volume of 0.3 mL.

Subretinal administration of voretigene neparvovec-rzyl to each eye must be performed on separate days within a close interval, but no fewer than 6 days apart.

Systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/d (maximum, 40 mg/d) recommended for a total of 7 days (starting 3 days before administration of voretigene neparvovec-rzyl to each eye), and followed by a tapering dose during the next 10 days.

Diagnosis of Biallelic RPE65-Mediated Inherited Retinal Dystrophies
Genetic testing is required to detect the presence of pathogenic or likely pathogenic variants in the RPE65 gene in individuals with documented vision loss. By definition, pathogenic or likely pathogenic variant(s) must be present in both copies of the RPE65 gene to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy.

A single RPE65 pathogenic or likely pathogenic variant found in the homozygous state (e.g., the presence of the same pathogenic or likely pathogenic variant in both copies alleles of the RPE65 gene) establishes a diagnosis of biallelic RPE65-mediated dystrophinopathy.

However, if 2 different RPE65 pathogenic or likely pathogenic variants are detected (e.g., compound heterogygous state), confirmatory testing such as segregation analysis by family studies may be required to determine the trans versus cis configuration (e.g., whether the 2 different pathogenic or likely pathogenic variants are found in different copies or in the same copy of the RPE65 gene). The presence of 2 different RPE65 pathogenic or likely pathogenic variants in separate copies of the RPE65 gene (trans configuration) establishes a diagnosis of biallelic RPE65-mediated dystrophinopathy. The presence of 2 different RPE65 pathogenic or likely pathogenic variants in only 1 copy of the RPE65 gene (cis configuration) is not considered a biallelic RPE65-mediated dystrophinopathy.

Next-generation sequencing and Sanger sequencing typically cannot resolve the phase (e.g., trans vs.cis configuration) when 2 RPE65 pathogenic or likely pathogenic variants are detected. In this scenario, additional documentation of the trans configuration is required to establish a diagnosis of biallelic RPE65-mediated inherited retinal dystrophy. Table PG1 provides a visual representation of the genetic status requirements to establish a diagnosis of RPE65-mediated inherited retinal dystrophy.

Table PG1. Genetic Diagnosis of RPE65-Mediated Inherited Retinal Dystrophy 

Genetic Counseling
Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Coding
Please see the Codes table for details.

Benefit Application 
BlueCard/National Account Issues 
State or federal mandates (e.g., Federal Employee Program) may dictate that certain U.S. Food and Drug Administration-approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only by their medical necessity. 

Rationale 
Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical uses of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The RCT is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Gene Therapy for RPE65 Variant-Associated Retinal Dystrophy
Clinical Context and Therapy Purpose
The purpose of gene therapy in patients who have retinal dystrophies caused by RPE65 variants is to restore the visual cycle so that vision is improved and patients can function more independently in their daily activities.

The question addressed in this evidence review is: Does gene augmentation therapy improve the net health outcome for patients with vision loss due to biallelic RPE65 variant-associated retinal dystrophy?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients with biallelic RPE65 variant-associated retinal dystrophy who have vision loss. Patients must still have sufficient, viable retinal cells to respond to the missing protein and restore visual function.

Interventions
The treatment being considered is gene augmentation therapy.

Voretigene neparvovec-rzyl (Luxturna) is an U.S. Food and Drug Administration (FDA) approved adeno-associated viral serotype 2 (AAV2) gene therapy vector that supplies a functional copy of the RPE65 gene within retinal pigment epithelium (RPE) cells.

Gene therapy is administered at highly specialized facilities with an active ophthalmology practice treating individuals with retinal dystrophies. Access is needed to medical retina specialists, vitreoretinal surgery expertise, and specialty pharmacies. Training programs for surgeons and pharmacists will likely be necessary.

Comparators
There are no other FDA approved pharmacologic treatments for RPE65 variant-associated retinal dystrophy. Supportive care such as correction of refractive error and visual aids and assistive devices may aid in performing daily activities.

Outcomes
Outcomes related to both how the eyes function and how an individual functions in vision-related activities of daily living are important for evaluating the efficacy of gene therapy for the treatment of retinal dystrophy. Relevant outcomes measures are listed in Table 2 below.

Table 2.  Health Outcome Measures Relevant to Retinal Dystrophy  

ETDRS: Early Treatment of Diabetic Retinopathy Study; log10 (cd.s/m2): logarithm of candela second per meter squared; logMAR: logarithm of the minimum angle of resolution; NEI: National Eye Institute; VFQ: Visual Function Questionnaire. 

Because the hallmark of the disease is nyctalopia, the manufacturer developed a novel outcome measure that assesses functional vision by evaluating the effects of illumination on speed and accuracy of navigation. The measure incorporates features of visual acuity (VA), visual field (VF), and light sensitivity. The Multi-Luminance Mobility Test (MLMT) grades individuals navigating a marked path while avoiding obstacles through various courses at 7 standardized levels of illumination, ranging from 1 to 400 lux (see examples in Table 3). Graders monitoring the navigation assign each course either a “pass” or “fail” score, depending on whether the individual navigates the course within 180 seconds with 3 or fewer errors. The lowest light level passed corresponds to an MLMT lux score, which ranges from 0 (400 lux) to 6 (1 lux). The score change is the difference between the MLMT lux score in year 1 and baseline. A positive score change corresponds to passing the MLMT at a lower light level. The reliability and content validity of the MLMT were evaluated in 60 (29 normal sighted, 31 visually impaired) individuals who navigated MLMT courses 3 times over 1 year.²⁰

Table 3. Light Levels for Multi-Luminance Mobility Test 

Adapted from the manufacturer’s FDA briefing materials.¹² 

Improvements in vision and function over a period of a year would demonstrate treatment efficacy. Evidence of durability of these effects over a period of several years or more is also needed given the progressive nature of the disease process. 

Review of Evidence 
Randomized Controlled Trials 
One gene therapy (voretigene neparvovec) for patients with biallelic RPE65 variant-associated retinal dystrophy has RCT evidence. The pivotal RCT, the efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE-65-mediated inherited retinal dystrophy (NCT00999609) for voretigene neparvovec was an open-label trial of patients ages 3 or older with biallelic RPE65 variants, VA worse than 20/60, and/or a VF less than 20^o in any meridian, with sufficient viable retinal cells.^12,14 Those patients meeting these criteria were randomized 2:1 to intervention (n = 21) or control (n = 10). The trial was conducted at a children’s hospital and university medical center. Patients were enrolled between 2012 and 2013. The intervention treatment group received sequential injections of 1.5E11 vg AAV2-hRPE65v2 (voretigene neparvovec) to each eye no more than 18 days apart (target, 12 days; standard deviation, 6 days). The injections were delivered in a total subretinal volume of 0.3 mL under general anesthesia. The control treatment group received voretigene neparvovec 1 year after the baseline evaluation. Patients received prednisone 1 mg/kg/d (max, 40 mg/d) for 7 days starting 3 days before injection in the first eye and tapered until 3 days before injection of the second eye at which point the steroid regimen was repeated. During the first year, follow-up visits occurred at 30, 90, 180 days, and 1 year. Extended follow-up is planned for 15 years. The efficacy outcomes were compared at 1 year. The primary outcome was the difference in mean bilateral MLMT score change. MLMT graders were masked to treatment group. The trial was powered to have greater than 90% power to detect a difference of 1 light level in the MLMT score at a 2-sided type I error rate of 5%. Secondary outcomes were hierarchically ranked: (1) difference in change in full-field light sensitivity threshold (FST) testing averaged over both eyes for white light; (2) difference in change in monocular (first eye) MLMT score change; (3) difference in change in VA averaged over both eyes. Patient-reported vision-related activities of daily living using a Visual Function Questionnaire (VFQ) and VF testing (Humphrey and Goldmann) were also reported. The VFQ has not been validated.

At baseline, the mean age was about 15 years old (range, 4 – 44 years) and approximately 42% of the participants were male. The MLMT passing level differed between the groups at baseline; about 60% passed at less than 125 lux in the intervention group versus 40% in the control group. The mean baseline VA was not reported but appears to have been between approximately 20/200 and 20/250 based on a figure in the manufacturer briefing document. One patient in each treatment group withdrew before the year 1 visit; neither received voretigene neparvovec. The remaining 20 patients in the intervention treatment and 9 patients in the control treatment groups completed the year 1 study visit. The intention-to-treat population included all randomized patients.

The efficacy outcome results at year 1 for the intention-to-treat population are shown in Table 4. In summary, the differences in change in MLMT and FST scores were statistically significant. No patients in the intervention group had worsening MLMT scores at 1 year compared with 3 patients in the control group. Almost two-thirds of the intervention arm showed maximal improvement in MLMT scores (passing at 1 lux) while no participants in the control arm were able to do so. Significant improvements were also observed in Goldmann III4e and Humphrey static perimetry macular threshold VF exams. The difference in change in VA was not statistically significant although the changes correspond to an improvement of about 8 letters in the intervention group and a loss of 1 letter in the control group. The original VA analysis used the Holladay method to assign values to off-chart results. Using, instead, the Lange method for off-chart results, the treatment effect estimate was similar, but variability estimates were reduced (difference in change, 7.4 letters; 95% confidence interval, 0.1 to 14.6 letters). No control patients experienced a gain of 15 or more letters (≤ 0.3 logMAR) at year 1 while 6 of 20 patients in the intervention group gained 15 or more letters in the first eye and 4 patients also experienced this improvement in the second eye. Contrast sensitivity data were collected but were not reported.

Table 4. Efficacy Outcomes Results at Year 1 in the Pivotal Phase 3 Trial of Gene Therapy for RPE65 Variant-Associated Retinal Dystrophy 

CI: confidence interval; FST: full-field light sensitivity threshold; MLMT: Multi-Luminance Mobility Test; NR: not reported; SD: standard deviation; VA: visual acuity; VF: visual field.
^a Corresponds to mean improvement of about 8 letters (i.e., » 1.5 lines).
^b Corresponds to mean loss of about 1 letter. 

The manufacturer briefing document reports results out to 2 years of follow-up.¹² In the intervention group, both functional vision and visual function improvements were observed for at least 2 years. At year 1, all 9 control patients received bilateral injections of voretigene neparvovec. After receiving treatment, the control group experienced improvement in MLMT (change score, 2.1; standard deviation, 1.6) and FST (change, -2.86; standard deviation, 1.49). VA in the control group improved an average of 4.5 letters between years 1 and 2. Overall, 72% (21/29) of all treated patients achieved the maximum possible MLMT improvement at 1 year following injection.

Two patients (1 in each group) experienced serious adverse events; both were unrelated to study participation. The most common ocular adverse events in the 20 patients treated with voretigene neparvovec were mild to moderate: elevated intraocular pressure, 4 (20%) patients; cataract, 3 (15%) patients; retinal tear, 2 (10%) patients; and eye inflammation, 2 (10%) patients. Several ocular adverse events occurred only in 1 patient each: conjunctival cyst, conjunctivitis, eye irritation, eye pain, eye pruritus, eye swelling, foreign body sensation, iritis, macular hold, maculopathy, pseudopapilledema, and retinal hemorrhage. One patient experienced a loss of VA (2.05 logMAR) in the first eye injected with voretigene neparvovec; the eye was profoundly impaired at 1.95 logMAR (approximately 20/1783 on a Snellen chart) at baseline.

Maguire et al. (2019) recently published the results of the open-label follow-on phase 1 study at year 4 and the phase 3 study at year 2.²¹ Mean (SD) MLMT lux score change was 2.4 (1.3) at 4 years compared with 2.6 (1.6) at 1 year after administration in phase 1 follow-on subjects (n = 8). Mean (SD) MLMT lux score change was 1.9 (1.0) at 2 years and 1.9 (1.0) at 1-year post-administration in the original intervention group (n = 20). The mean (SD) MLMT lux score change was 2.1 (1.6) at 1-year post-administration in control subjects (n = 9). Therefore, durability for up to 4 years has been reported, with observation ongoing.

Section Summary: Randomized Controlled Trials
In the pivotal RCT, patients in the voretigene neparvovec group demonstrated greater improvements on the MLMT, which measures the ability to navigate in dim lighting conditions, compared with patients in the control group. The difference in mean improvement was both statistically significant and larger than the a priori defined clinically meaningful difference. Most other measures of visual function were also significantly improved in the voretigene neparvovec group compared with the control group, except VA. Improvements seemed durable over a period of 2 years. The adverse events were mostly mild to moderate; however, 1 patient lost 2.05 logMAR in the first eye treated with voretigene neparvovec by the 1-year visit. There are limitations in the evidence. There is limited follow-up available. Therefore, long-term efficacy and safety are unknown. The primary outcome measure has not been used previously in RCTs and has limited data to support its use. Only the MLMT assessors were blinded to treatment assignment, which could have introduced bias assessment of other outcomes. The modified VFQ is not validated, so effects on quality of life remain uncertain.

Early Phase Trials
Based on preclinical studies performed in animals, early phase studies of gene augmentation therapy for RPE65-associated Leber congenital amaurosis were initiated in 2007 by several independent groups of investigators. The initial reports of the results of these studies began to be published in 2008. The studies did not have an untreated control group, but several used a patient’s untreated eye as a control. Characteristics of the studies are shown in Table 5. Most cohorts included in the studies have been followed in several publications. The baseline visual function, gene constructs, vector formulations, and surgical approaches used by different investigators have varied. Voretigene neparvovec was administered to the Children’s Hospital of Pennsylvania cohort.

Table 5. Characteristics of Phase 1/2 studies of Gene Therapy for RPE65 Variant-Associated Retinal Dystrophy

AAV: adeno-associated viruses; CHOP: Children’s Hospital of Pennsylvania; vg: vector genomes; LCA: Leber congenital amaurosis; NCT: national clinical trial; SECORD: severe early-childhood onset retinal degeneration; VA: visual acuity; vg: vector genomes.

Voretigene Neparvovec
CHOP Cohort
Several publications have described various outcomes and subgroups of the cohort included in the phase 1/2 studies of voretigene neparvovec.^{22,23,24,25,26,27,28,29,30} Early results showed improvement in subjective and objective measurements of vision (i.e., dark adaptometry, pupillometry, electroretinography, nystagmus, ambulatory behavior).^23,24,25 Although the samples were too small for subgroups analyses, the investigators noted that the greatest improvement appeared to be in children. Three-year follow-up of 5 of the first injected eyes (in patients from Italy) was reported.²⁷ There was a statistically significant improvement in VA between baseline and 3 years (p < 0.001). All patients maintained increased VF and a reduction of the nystagmus frequency compared with baseline. Three-year follow-up is also available for both the originally injected eye and contralateral eye in 11 patients.²⁹ Statistically significant improvements in mean mobility and full-field light sensitivity persisted to year 3. The changes in VA were not significant. Ocular adverse events were mostly mild (dellen formation in 3 patients and cataracts in 2 patients). One patient developed bacterial endophthalmitis.

Long-term follow-up for safety was reported in the manufacturer’s FDA briefing documents.⁴⁷ This follow-up included the 12 patients in the phase 1 study as well as the 29 patients in the phase 3 study. Two, phase 2 patients had 9 years of follow-up, 8 patients had 8 years of follow-up, and all 12 patients had at least 7 years of follow-up. Four, phase 3 patients had 4 years of follow-up and the remaining patients had between 2 and 3 years of follow-up. No deaths occurred. The adverse events tended to occur early and diminish and resolve over time. While all patients experienced at least 1 adverse event, 85% of the adverse events reported were of mild or moderate intensity. Fourteen serious adverse events were reported by 9 patients, but none were assessed as related to the product; 1 was assessed as related to the administration procedure (retinal disorder) and another as related to a periocular steroid injection (increased intraocular pressure). Ocular adverse events that were assessed as related to treatment, required clinical management or impacted the benefit-risk profile occurred in 81 eyes (41 patients): macular disorders (9 eyes, 7 patients), increased intraocular pressure (10 eyes, 8 patients), retinal tear (4 eyes, 4 patients), infections/inflammation (5 eyes, 3 patients), and cataracts (16 eyes, 9 patients). Nine eyes in 7 patients had a 15-letter or more loss in VA. Four of the eyes had VA loss within a month of surgery, and the other 5 eyes had VA loss at or after the first year. No deleterious immune responses were observed in any patients.

Other Gene Therapies
London Cohort
At least 4 publications following the London cohort are available.^31,32,33,34 Preliminary results showed increased retinal sensitivity in 1 of 3 participants. After 3 years of follow-up in all 12 patients, 2 patients had substantial improvements (10 to 100 times as high) in rod sensitivity that peaked around 12 months after treatment and then declined. There was no consistent improvement overall in VA. A decline in VA of 15 letters or more occurred in 2 patients. Intraocular inflammation and/or immune responses occurred in 5 of the 8 patients who received the higher dose and in 1 of 4 patients who received the lower dose. The immune response was deleterious in 1 patient.

Scheie/Shands Cohort
Results for patients in the Scheie/Shands cohort have also been reported in many publications.^{35,36,37,38,39,40,41,42} Visual function was reported to have improved in all patients. Dark-adapted FST showed highly significant increases from baseline in the treated eye and no change in the control eye. Cone and rod sensitivities improved significantly in the treated regions of the retina at 3 months, and these improvements were sustained through 3 years. Small improvements in VA were reported, and the improvement appeared to be largest in eyes with the lowest baseline acuities. Retinal detachment and persistent choroidal effusions were reported in 1 patient each; both were related to surgery. However, at a mean follow-up of 4.6 years, the investigators noted that while improvements in vision were maintained overall, the photoreceptors showed progressive degeneration. In 3 patients followed for 5 to 6 years, improvements in vision appeared to peak between 1 and 3 years after which there was a decline in the area of improved sensitivity in all 3 patients.

Israel Cohort
Although the registration for this study indicates that 10 patients were enrolled and followed for 3 years, only the short-term results of 1 patient have been reported.⁴³ In that patient, there was an increase in vision as early as 15 days after treatment.

Casey/UMass Cohort
Two publications have reported results for the Casey/UMass cohort.^44,45 In 9 of 12 patients, there was improvement in 1 or more measures of visual function. VA increased in 5 patients, 30° VF hill of vision increased in 6 patients, total VF hill of vision increased in 5 patients, and kinetic VF area increased in 3 patients. The improvements persisted to 2 years in most patients. National Eye Institute VFQ-25 scores improved in 11 of 12 patients. Subconjunctival hemorrhage occurred in 8 patients, and ocular hyperemia occurred in 5 patients.

Results at 5 years following treatment were available for 11/12 patients, with 1 patient lost to follow-up.⁴⁵ Improvements in VA and static perimetry persisted during years 3 – 5 in all 4 pediatric patients, with no consistent changes in kinetic perimetry. In 2 of these patients, VA in the untreated eye also improved in years 3 – 5. Most adult subjects had no consistent changes in VA or static perimetry. In 4 of 5 adult subjects with poor baseline VA, progressive loss of vision in 1 or both eyes was noted during years 3 – 5. No significant adverse safety events were observed with results providing further evidence that treatment at an early age promotes improved outcomes.

Nantes Cohort
One publication has described results of the Nantes cohort.⁴⁶ In 8 of 9 patients, there was an improvement in VA of more than 2.5 letters at 1 year after injection; improvements were greatest for patients with a baseline VA between 7 and 31 letters and those with nystagmus. After 2 years of follow-up, the surface area of the VF had increased in 6 patients, decreased in 2 patients, and was the same in 1 patient. For the 6 patients with 3 years of follow-up, 4 continued to have improvements in VF.

Section Summary: Early Phase Trials
Voretigene neparvovec appears to have durable effects to at least 4 years in a small number of patients with follow-up.

Other gene therapies tested in early phase trials have shown improvements in retinal function but the variable durability of effect; some patients from 2 cohorts who initially experienced improvements have subsequently experienced declines after 1 to 3 years.

Adverse events of gene therapy tended to occur early; most are mild to moderate and diminished over time. Seven of 41 patients treated with voretigene neparvovec have had a loss of 15 letters or more in at least 1 eye. Most studies have reported minimal immune response.

Summary of Evidence
For individuals who have vision loss due to biallelic RPE65 variant-associated retinal dystrophy who receive gene therapy, the evidence includes RCTs and uncontrolled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Biallelic RPE65 variant-associated retinal dystrophy is a rare condition and, as such, it is recognized that there will be particular challenges in generating evidence, including recruitment for adequately powered RCTs, validation of novel outcome measures, and obtaining longer-term data on safety and durability. There are no other U.S. Food and Drug Administration approved pharmacologic treatments for this condition. One RCT (N = 31) comparing voretigene neparvovec with a control demonstrated greater improvements on the Multi-Luminance Mobility Test, which measures the ability to navigate in dim lighting conditions. Most other measures of visual function were also significantly improved in the voretigene neparvovec group compared with the control group. Adverse events were mostly mild to moderate. However, there is limited follow-up available. Therefore, the long-term efficacy and safety are unknown. Based on a small number of patients from early phase studies, voretigene neparvovec appears to have durable effects to at least 4 years. Other gene therapies tested in early phase trials have shown improvements in retinal function but variable durability of effect; some patients from 2 cohorts who initially experienced improvements have subsequently experienced declines after 1 to 3 years. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

The purpose of the remaining sections in Supplemental Information is to provide reference material regarding existing practice guidelines and position statements, U.S. Preventive Services Task Force Recommendations and Medicare National Coverage Decisions and registered, ongoing clinical trials. Inclusion in the Supplemental Information does not imply endorsement and information may not necessarily be used in formulating the evidence review conclusions.

Guidelines or position statements will be considered for inclusion in Supplemental Information if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Practice Guidelines and Position Statements
National Institute for Health and Care Excellence
In 2019, the National Institute for Health and Care Excellence published guidance for the use of voretigene neparvovec (Luxturna) in the treatment of inherited retinal dystrophies caused by RPE65 gene mutations.⁴⁸ The treatment is recommended for individuals with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations who have sufficient viable retinal cells. Despite uncertainty surrounding long-term durability, the committee felt this intervention is likely to provide important clinical benefits for individuals afflicted with inherited retinal dystrophies.

U.S. Preventive Services Task Force Recommendations
Not applicable

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 6. 

Table 6. Summary of Key Trials 

NCT: national clinical trial.
^a Denotes industry-sponsored or cosponsored trial.

References 

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. Nov 18 2006; 368(9549): 1795-809. PMID 17113430
2. Jin M, Li S, Moghrabi WN, et al. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell. Aug 12 2005; 122(3): 449-59. PMID 16096063
3. Naso MF, Tomkowicz B, Perry WL, et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. Aug 2017; 31(4): 317-334. PMID 28669112
4. Stone EM. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. Dec 2007; 144(6): 791-811. PMID 17964524
5. Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol. Jul-Aug 2004; 49(4): 379-98. PMID 15231395
6. den Hollander AI, Roepman R, Koenekoop RK, et al. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. Jul 2008; 27(4): 391-419. PMID 18632300
7. Astuti GD, Bertelsen M, Preising MN, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. Eur J Hum Genet. Jul 2016; 24(7): 1071-9. PMID 26626312
8. Kumaran N, Moore AT, Weleber RG, et al. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. Sep 2017; 101(9): 1147-1154. PMID 28689169
9. Haim M. Epidemiology of retinitis pigmentosa in Denmark. Acta Ophthalmol Scand Suppl. 2002; (233): 1-34. PMID 11921605
10. Morimura H, Fishman GA, Grover SA, et al. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A. Mar 17 1998; 95(6): 3088-93. PMID 9501220
11. United States Census Bureau. U.S. and World Population Clock. 2020; https://www.census.gov/popclock/. Accessed November 19, 2020.
12. FDA Advisory Committee Briefing Document: Spark Therapeutics, Inc, LuxturnaTM (voretigene neparvovec). 2017; https://www.fda.gov/media/108385/download. Accessed November 19, 2020.
13. Campa C, Gallenga CE, Bolletta E, et al. The Role of Gene Therapy in the Treatment of Retinal Diseases: A Review. Curr Gene Ther. 2017; 17(3): 194-213. PMID 29149824
14. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. Aug 26 2017; 390(10097): 849-860. PMID 28712537
15. Beck RW, Maguire MG, Bressler NM, et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. Oct 2007; 114(10): 1804-9. PMID 17908590
16. Bittner AK, Gould JM, Rosenfarb A, et al. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients. Clin Exp Optom. May 2014; 97(3): 240-7. PMID 24773463
17. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. Nov 2001; 108(11): 1943-53. PMID 11713061
18. Gillespie BW, Musch DC, Niziol LM, et al. Estimating minimally important differences for two vision-specific quality of life measures. Invest Ophthalmol Vis Sci. Jun 06 2014; 55(7): 4206-12. PMID 24906863
19. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol. Jul-Aug 2007; 14(4): 205-15. PMID 17896299
20. Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. Apr 2018; 46(3): 247-259. PMID 28697537
21. Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. Sep 2019; 126(9): 1273-1285. PMID 31443789
22. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. May 22 2008; 358(21): 2240-8. PMID 18441370
23. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. Nov 07 2009; 374(9701): 1597-605. PMID 19854499
24. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. Mar 2010; 18(3): 643-50. PMID 19953081
25. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest. Jun 2011; 121(6): 2160-8. PMID 21606598
26. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. Feb 08 2012; 4(120): 120ra15. PMID 22323828
27. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. Jun 2013; 120(6): 1283-91. PMID 23474247
28. Ashtari M, Zhang H, Cook PA, et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis. Sci Transl Med. Jul 15 2015; 7(296): 296ra110. PMID 26180100
29. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. Aug 13 2016; 388(10045): 661-72. PMID 27375040
30. Ashtari M, Nikonova ES, Marshall KA, et al. The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients. Ophthalmology. Jun 2017; 124(6): 873-883. PMID 28237426
31. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. May 22 2008; 358(21): 2231-9. PMID 18441371
32. Stieger K. tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. Aug 2010; 12(4): 471-7. PMID 20677098
33. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. May 14 2015; 372(20): 1887-97. PMID 25938638
34. Ripamonti C, Henning GB, Robbie SJ, et al. Spectral sensitivity measurements reveal partial success in restoring missing rod function with gene therapy. J Vis. 2015; 15(15): 20. PMID 26605849
35. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. Oct 2008; 19(10): 979-90. PMID 18774912
36. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. Sep 30 2008; 105(39): 15112-7. PMID 18809924
37. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. Sep 2009; 20(9): 999-1004. PMID 19583479
38. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med. Aug 13 2009; 361(7): 725-7. PMID 19675341
39. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. Jan 2012; 130(1): 9-24. PMID 21911650
40. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. Feb 05 2013; 110(6): E517-25. PMID 23341635
41. Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci. Dec 23 2014; 56(1): 526-37. PMID 25537204
42. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. May 14 2015; 372(20): 1920-6. PMID 25936984
43. Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther. Dec 2010; 21(12): 1749-57. PMID 20604683
44. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. Ophthalmology. Jul 2016; 123(7): 1606-20. PMID 27102010
45. Pennesi ME, Weleber RG, Yang P, et al. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. Hum Gene Ther. Dec 2018; 29(12): 1428-1437. PMID 29869534
46. Le Meur G, Lebranchu P, Billaud F, et al. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. Mol Ther. Jan 03 2018; 26(1): 256-268. PMID 29033008
47. Spark Therapeutics. FDA Advisory Committee Briefing Document: Spark Therapeutics, Inc, LuxturnaTM (voretigene neparvovec). 2017; https://www.fda.gov/media/108385/download. Accessed December 9, 2019.
48. National Institute for Health and Care Excellence (NICE). Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11). October 9, 2019. http://nice.org.uk/guidance/hst11. Accessed November 19, 2020. 

Coding Section 

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2018 Forward